President Trump has escalated his trade war, this time hitting the pharmaceutical sector. Starting October, all branded and patented drug imports into the U.S. will face a steep 100% tariff. India, the largest supplier of medicines to America, is likely to be impacted the most. While generic medicines remain exempt for now, Washington has already initiated a wide-ranging probe into pharma imports, sparking concerns of tighter restrictions ahead. With Indian companies accounting for nearly one-third of U.S. drug supplies, pressure is mounting on them to shift manufacturing to American soil, invest in local plants, and bear higher costs. Asian markets immediately felt the tremors, with pharma stocks tumbling. The consequence is worrying, Indian pharmaceutical firms risk losing competitiveness, while U.S. patients could end up paying significantly higher prices for critical and life-saving medicines.